June 9, 2020 / 8:12 PM / 2 months ago

BRIEF-Merck Provides Update On Phase 3 Keynote-361 Trial Evaluating Keytruda

June 9 (Reuters) - Merck & Co Inc:

* MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-361 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

* MERCK & CO INC - PHASE 3 KEYNOTE-361 TRIAL EVALUATING KEYTRUDA DID NOT MEET ITS PRE-SPECIFIED DUAL PRIMARY ENDPOINTS

* MERCK & CO - SAFETY PROFILE OF KEYTRUDA IN PHASE 3 KEYNOTE-361 TRIAL CONSISTENT WITH PREVIOUSLY REPORTED STUDIES, NO NEW SAFETY SIGNALS IDENTIFIED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below